Pozdravljeni!

V clankih sem zasledila, da je substanca Vinpocetin (Cavinton) spodbujevalec pomnenja. Ker sem studentka me zelo mika, da bi pricela z jemanjem teh tablet za boljse pomnenje. Kaj menite o tem vi? Ali mislite, da je zdravilo varno in ali se lahko uziva socasno ob jemanju tbl Zolloft.

Hvala in lep pozdrav!

Spoštovana p.s.i,
Vinpocentin je zdravilo, ki se je prd dvajsetimi leti pojavilo na Madžarskem in sicer najprej kot sredstvo za boljšo prekrvo očesa.Kasneje so pričakovanje razširili še na domnevno ugoden učinek na delovanje možganov.Na svetovnem spletu imate 2470 omemb zdravila, v glavnem komercialne narave.Pri nas zdravilo ni registrirano za uporabo.
V zvezi z boljšim študijem pa tole: pri svojem delu s študenti redno srečujem ljudi, ki bi radi ubrali neko bližnjico, po možnosti dosegli znanje s čimmanjšim lastnim vloženim trudom oz s pomočjo kemičnih pomagal. Tam je vedno vprašljiva motivacija za študij, ne pa sposobnosti pomnenja. Če je nekdo uspešno oončal srednje šilanje, ki temelji na memoriranju, ne bo odpovedal pri študiju,kjer gre za logično povezovanje in le dopolnjevanje znanih olvirov.Ljudje z ADHD torej izkazanimi težavami s koncentracijo in pomnenjem, te svoje težave manifestirajo že pred osnovno šolo ali takoj ob vstopu.Tam psihofarmakoterapija prinaša tudi uspehe.Kadar pa je pri šudiju razlog za neuspešnost pomnjkljiva motivacija so mehanizmi za spodbudo predvsem psihološke ne pa biokemične narave.Vprašajte se, ali vas izbrani študij res veseli, oziroma ali bi vam bolje ustrezala sprememba smeri.

Najprej hvala za odgovor!

Kar se tiče smeri, ki sem jo izbrala za študij sem vsekakor prepričana, da je to prava smer, ki me veseli. Problem pa je v tem, da mi pogosto primanjkuje časa saj sem mati 4 letne deklice, zaposlena, poleg tega študiram na Pravni fakulteti v Lj.
Zaradi zelo stresnega zivljenja v zadnjih nekaj letih (kronična bolezen hčerke, ločitev) opažam težave pri študiju in sicer kot pomanjkanje koncentracije in spomina.
Ponovno vas prosim za nasvet in informacije o možnih posledicah jemanja omenjenih tablet.

Hvala in lep pozdrav!

Hvala za odgovor!

Vsekakor sem prepričana, da je smer, ki sem jo izbrala za študij ustrezna in verjetno edina, ki me veseli. Pa vendar opažam zadnje čase zaradi zelo stresnega življenja v zadnjih 2 letih (kronična bolezen hčerke, ločitev, smrt sestre) težave s koncentracijo in spominom.
Ker sem mati 4 letne hčerke, zaposlena in študentka prava mi pogosto tudi primanjkuje časa, pojavlja se utrujenost.
Ko sem zasledila informacije o piracetamu se mi je zdelo primerno, da bi zdravilo preiskusila, če seveda nima kakšnih hujših stranskih učinkov. Seveda pa ima tako kot vsa zdravila (tudi npr. kontrac. tbl, ki jih vsi uživamo) možne stranske učinke.

Ponovno vas prosim, da mi napišete vaše mnenje o uživanju omenjenih zdravil oz. ali so zdravila varna in učinkovita.

Hvala in lep pozdrav!

Spoštovani p.s.i.Menim sicer, da ste si naložili preveč bremen hkrati
in vam zato priporočam, da si za študij organizirate dovolj časa.Glede na članek, ki sledi, se vam stranskih učinkov ob jemanju vinpocetina ni treba bati.Glavni učinek pa je pemo sorazmeren stanju vašega krvnega obtoka .

Vinpocetine

Vinpocetine: “Viagra for the Brain”

Reprinted from the So Young Newsletter

Vinpocetine, powerful brain de-ager, tagged as “Viagra for the Brain,” is increasing worldwide in the treatment of cognitive deficits related to “normal” aging.

Formerly available as pricey European smart drug Cavinton (aka ARGH-4405 and Ceractin), the natural substance has recently become available as a low-cost nutritional supplement in the U.S.

Vinpocetine takes aim at the brain much the same way Viagra targets the genitals. The mechanism in both improves the blood flow, inhibiting a phosphodiesterase enzyme that degrades cyclic GMP to relax constricted arteries and smooth muscle. With Vinpocetine, cerebral microcirculation and metabolism improve and brain ATP (the cellular energy molecule) production increases along with the utilization of glucose (cellular energy food) and oxygen.

Derived from vincamine,an extract of the dwarf periwinkle plant vinca minor, the natural substance is backed by more than 20 years of clinical data for the treatment of cerebrovascular disorders and symptoms related to senility.

A “proven” long-and short-term memory booster and eyesight enhancer, its extensive medical use in cerebral circulatory disorders includes: memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness, headache, cerebro-vestibular (inner ear) problems and sensorineural hearing impairment.

Vinpocetine has “essentially revolutionized the treatment of stroke and vascular dementia,” reports David Perlmutter, M.D., “even when administered long after the initial stroke event.” Its effectiveness is likely due in part to its remarkable ability to dilate brain arteries, enhancing brain blood flow in patients with cerebrovascular disease. This improves delivery of life-giving oxygen to even marginally functioning areas of the brain.

A potent antioxidant, Vinpocetine counters “ongoing” free radical brain damage. It also reduces the “stickiness” of blood cell and platelets, to inhibit clumping tendencies (thromboses, blood clots) and the risk of stroke. Additionally, it increases elasticity of the erythrocytes, which means that red blood cells become more flexible. This enhances their ability to flow even to damaged areas of the brain.

Marketed as Cavinton in Europe by Gedeon Richter of Hungary, a series of studies conducted by the company involved 882 patients with neurological disorders ranging from stroke to cerebral insufficiency. Significant improvements were found in 62% of the patients. In one study cerebral insufficiency patients were instructed to memorize a list of 10 words. Without supplementation, the patients could memorize an average of 6 words. After a month on Vinpocetine, the average moved up to 10 words.

In another double-blind study, 22 elderly patients with central nervous system degenerative disorders were treated with Vinpocetine or placebo. Patients receiving 10 mg. of Vinpocetine three times a day for 30 days, then 5 mg. three times a day for 60 days, scored consistently better in all evaluations. CGI assessments indicated that the severity of illness decreased in 73% of the patients in the Vinpocetine group at day 30; 77% at day 90; improvement seen in 77% at day 30 and 87% at day 90. The improvement in 59% Vinpocetine-treated patients was rated good to excellent. No serious side effects were noted.

Vinpocetine’s effect on memory function was also studied in 50 patients with cerebral circulation disturbances. Improved cerebral circulation was observed after intravenous and oral administration of Vinpocetine; blood flow was most markedly increased in the brain’s gray matter. Memory capacity also improved after one month of treatment, longer-term use being associated with alleviation or complete disappearance of neurological deficit symptoms. No side effects attributed to the drug were observed.

A study to ascertain how Vinpocetine boosts cognition was undertaken in rats. A significant increase in the firing rate of neurons was noted. Since the dose of Vinpocetine used to increase electrical firing corresponded to the dose range that produced memory-enhancing effects, the results offer direct electrophysiological evidence that Vinpocetine increases the activity of ascending noradrenergic pathways, and that this effect may be related to the cognitive-enhancing characteristics of the compound.

The cognitive enhancer is also used to treat acute or chronic ophthalmological diseases of various origins, with visual acuity improving in 70% of the subjects. Product literature for Cavinton indicates its usage in cases of clogged arteries in the retina and vascular layer, in cases of degenerative changes of the yellow spot (macula) caused primarily by arteriosclerosis or angiospasm, and in cases of partial thrombosis as well as secondary glaucoma caused by the clogging of blood vessels.

Moreover, a study showed beneficial effects in protecting the retina against the hepatitis B virus (a virus that infects the heart muscle, retina, and other body parts, not only the liver).

Additionally, Vinpocetine also has been documented to partially protect against excitotoxicity induced by a wide range of glutamate-related neuro-toxins.

Vinpocetine may hold potential value for individuals who drink in excess, according to a study showing that Vinpocetine administered to rats inhibited the development of gastric lesions induced by ethanol. (Vinpocetine is a popular drug used by alcoholics in Russia to recover from gastric and neurological ethanol-induced toxicity.)

Vinpocetine has also been used successfully in offsetting space-motion sickness in experimental test subjects in both the Soviet/Russian and U.S.-manned space programs.

Beyond its medical and protective functions, Vinpocetine can boost short-term memory in healthy subjects. In a double-blind crossover study of normal, healthy women volunteers between the ages of 25 and 40 demonstrated Vinpocetine’s incredible effects. One hour after taking 40 mg. of Vinpocetine, the volunteers took the Sternberg Memory Scanning Test–a short-term memory computer-administered test. Each woman was shown one to three digits on a computer screen. One minute later, each was shown a long string of digits and was instructed to indicate whether any of the first numbers were included on the second long string. Memory time was then assessed. Women taking the placebo averaged a response in 700 milliseconds. Those taking Vinpocetine averaged under 450 milliseconds.

Gedeon Richter promotes Vinpocetine as the only drug that improves cerebral metabolism (glucose and oxygen uptake), tolerance of hypoxia (deficient blood oxygenation), ATP concentration, norepinephrine and serotin turnover, and cerebral micro-circulation. The company also claims that Vinpocetine selectively increases blood flow to the brain, improving blood flow to the impaired area without lowering blood flow to other parts of the body.

Recent studies further demonstrate that Vinpocetine offers significant and direct protection against neurological damage caused by aging. The molecular evidence indicates that the neuroprotective action of Vinpocetine is related to its ability to maintain brain cell electrical conductivity and to protect against damage caused by excessive intracellular release of calcium.

Literature shows Vinpocetine as sharing the effects of, and comparing favorably to, placebo, vincamine, papaverine, DHT (Hydergine), xanthinolnicotinate, meclophenoxate, cinnarizine, niacin, cyclandelate, difenidol, and ifenprodil.

As to its safety, more than 100 studies conducted by Gedeon Richter, have shown Vinpocetine has no drug interactions, no toxicity, and is generally very safe. Incidence of side effects using the oral supplement in humans is usually less than 1% of a study’s participants, with the unwanted effects usually disappearing with continued use. Adverse effects are rare but may include hypotenions (low blood pressure), dry mouth, weakness, and tachycardia.

A study of infants who suffered severe brain damage caused by birth trauma indicates its safety and efficacy. The study showed the infants administered Vinpocetine indicated a significant reduction or disappearance of symptoms, a decrease of intracranial hypertension, and normalization of psychomotor development.

Dosage is generally placed at 30-40 mg. daily or as prescribed by your health professional. Cost for 90/10 mg. capsules is around $18. Usage is not advised if pregnant.

While it is disquieting to think that most of us around age 30 experience a progressive decline in cognitive function, it is more than comforting to know that this is not our inevitable fate. Research and actual case studies have indicated that brain cell death can be prevented with Vinpocetine. It is conceivable to speculate that rather than face neurological impairment by the time we’re in our 80s and 90s, we can continue to develop and increase in intelligence.

(copyright Julia Busch, 2000)

***

Disclaimer

1. Consult a physician for the treatment of any disease or physical disorder.

2. We are required by law

Spoštovani p.s.i.Menim sicer, da ste si naložili preveč bremen hkrati
in vam zato priporočam, da si za študij organizirate dovolj časa.Glede na članek, ki sledi, se vam stranskih učinkov ob jemanju vinpocetina ni treba bati.Glavni učinek pa je pemo sorazmeren stanju vašega krvnega obtoka .

Vinpocetine

Vinpocetine: “Viagra for the Brain”

Reprinted from the So Young Newsletter

Vinpocetine, powerful brain de-ager, tagged as “Viagra for the Brain,” is increasing worldwide in the treatment of cognitive deficits related to “normal” aging.

Formerly available as pricey European smart drug Cavinton (aka ARGH-4405 and Ceractin), the natural substance has recently become available as a low-cost nutritional supplement in the U.S.

Vinpocetine takes aim at the brain much the same way Viagra targets the genitals. The mechanism in both improves the blood flow, inhibiting a phosphodiesterase enzyme that degrades cyclic GMP to relax constricted arteries and smooth muscle. With Vinpocetine, cerebral microcirculation and metabolism improve and brain ATP (the cellular energy molecule) production increases along with the utilization of glucose (cellular energy food) and oxygen.

Derived from vincamine,an extract of the dwarf periwinkle plant vinca minor, the natural substance is backed by more than 20 years of clinical data for the treatment of cerebrovascular disorders and symptoms related to senility.

A “proven” long-and short-term memory booster and eyesight enhancer, its extensive medical use in cerebral circulatory disorders includes: memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness, headache, cerebro-vestibular (inner ear) problems and sensorineural hearing impairment.

Vinpocetine has “essentially revolutionized the treatment of stroke and vascular dementia,” reports David Perlmutter, M.D., “even when administered long after the initial stroke event.” Its effectiveness is likely due in part to its remarkable ability to dilate brain arteries, enhancing brain blood flow in patients with cerebrovascular disease. This improves delivery of life-giving oxygen to even marginally functioning areas of the brain.

A potent antioxidant, Vinpocetine counters “ongoing” free radical brain damage. It also reduces the “stickiness” of blood cell and platelets, to inhibit clumping tendencies (thromboses, blood clots) and the risk of stroke. Additionally, it increases elasticity of the erythrocytes, which means that red blood cells become more flexible. This enhances their ability to flow even to damaged areas of the brain.

Marketed as Cavinton in Europe by Gedeon Richter of Hungary, a series of studies conducted by the company involved 882 patients with neurological disorders ranging from stroke to cerebral insufficiency. Significant improvements were found in 62% of the patients. In one study cerebral insufficiency patients were instructed to memorize a list of 10 words. Without supplementation, the patients could memorize an average of 6 words. After a month on Vinpocetine, the average moved up to 10 words.

In another double-blind study, 22 elderly patients with central nervous system degenerative disorders were treated with Vinpocetine or placebo. Patients receiving 10 mg. of Vinpocetine three times a day for 30 days, then 5 mg. three times a day for 60 days, scored consistently better in all evaluations. CGI assessments indicated that the severity of illness decreased in 73% of the patients in the Vinpocetine group at day 30; 77% at day 90; improvement seen in 77% at day 30 and 87% at day 90. The improvement in 59% Vinpocetine-treated patients was rated good to excellent. No serious side effects were noted.

Vinpocetine’s effect on memory function was also studied in 50 patients with cerebral circulation disturbances. Improved cerebral circulation was observed after intravenous and oral administration of Vinpocetine; blood flow was most markedly increased in the brain’s gray matter. Memory capacity also improved after one month of treatment, longer-term use being associated with alleviation or complete disappearance of neurological deficit symptoms. No side effects attributed to the drug were observed.

A study to ascertain how Vinpocetine boosts cognition was undertaken in rats. A significant increase in the firing rate of neurons was noted. Since the dose of Vinpocetine used to increase electrical firing corresponded to the dose range that produced memory-enhancing effects, the results offer direct electrophysiological evidence that Vinpocetine increases the activity of ascending noradrenergic pathways, and that this effect may be related to the cognitive-enhancing characteristics of the compound.

The cognitive enhancer is also used to treat acute or chronic ophthalmological diseases of various origins, with visual acuity improving in 70% of the subjects. Product literature for Cavinton indicates its usage in cases of clogged arteries in the retina and vascular layer, in cases of degenerative changes of the yellow spot (macula) caused primarily by arteriosclerosis or angiospasm, and in cases of partial thrombosis as well as secondary glaucoma caused by the clogging of blood vessels.

Moreover, a study showed beneficial effects in protecting the retina against the hepatitis B virus (a virus that infects the heart muscle, retina, and other body parts, not only the liver).

Additionally, Vinpocetine also has been documented to partially protect against excitotoxicity induced by a wide range of glutamate-related neuro-toxins.

Vinpocetine may hold potential value for individuals who drink in excess, according to a study showing that Vinpocetine administered to rats inhibited the development of gastric lesions induced by ethanol. (Vinpocetine is a popular drug used by alcoholics in Russia to recover from gastric and neurological ethanol-induced toxicity.)

Vinpocetine has also been used successfully in offsetting space-motion sickness in experimental test subjects in both the Soviet/Russian and U.S.-manned space programs.

Beyond its medical and protective functions, Vinpocetine can boost short-term memory in healthy subjects. In a double-blind crossover study of normal, healthy women volunteers between the ages of 25 and 40 demonstrated Vinpocetine’s incredible effects. One hour after taking 40 mg. of Vinpocetine, the volunteers took the Sternberg Memory Scanning Test–a short-term memory computer-administered test. Each woman was shown one to three digits on a computer screen. One minute later, each was shown a long string of digits and was instructed to indicate whether any of the first numbers were included on the second long string. Memory time was then assessed. Women taking the placebo averaged a response in 700 milliseconds. Those taking Vinpocetine averaged under 450 milliseconds.

Gedeon Richter promotes Vinpocetine as the only drug that improves cerebral metabolism (glucose and oxygen uptake), tolerance of hypoxia (deficient blood oxygenation), ATP concentration, norepinephrine and serotin turnover, and cerebral micro-circulation. The company also claims that Vinpocetine selectively increases blood flow to the brain, improving blood flow to the impaired area without lowering blood flow to other parts of the body.

Recent studies further demonstrate that Vinpocetine offers significant and direct protection against neurological damage caused by aging. The molecular evidence indicates that the neuroprotective action of Vinpocetine is related to its ability to maintain brain cell electrical conductivity and to protect against damage caused by excessive intracellular release of calcium.

Literature shows Vinpocetine as sharing the effects of, and comparing favorably to, placebo, vincamine, papaverine, DHT (Hydergine), xanthinolnicotinate, meclophenoxate, cinnarizine, niacin, cyclandelate, difenidol, and ifenprodil.

As to its safety, more than 100 studies conducted by Gedeon Richter, have shown Vinpocetine has no drug interactions, no toxicity, and is generally very safe. Incidence of side effects using the oral supplement in humans is usually less than 1% of a study’s participants, with the unwanted effects usually disappearing with continued use. Adverse effects are rare but may include hypotenions (low blood pressure), dry mouth, weakness, and tachycardia.

A study of infants who suffered severe brain damage caused by birth trauma indicates its safety and efficacy. The study showed the infants administered Vinpocetine indicated a significant reduction or disappearance of symptoms, a decrease of intracranial hypertension, and normalization of psychomotor development.

Dosage is generally placed at 30-40 mg. daily or as prescribed by your health professional. Cost for 90/10 mg. capsules is around $18. Usage is not advised if pregnant.

While it is disquieting to think that most of us around age 30 experience a progressive decline in cognitive function, it is more than comforting to know that this is not our inevitable fate. Research and actual case studies have indicated that brain cell death can be prevented with Vinpocetine. It is conceivable to speculate that rather than face neurological impairment by the time we’re in our 80s and 90s, we can continue to develop and increase in intelligence.

(copyright Julia Busch, 2000)

***

Disclaimer

Spoštovani p.s.i.Menim sicer, da ste si naložili preveč bremen hkrati
in vam zato priporočam, da si za študij organizirate dovolj časa.Glede na članek, ki sledi, se vam stranskih učinkov ob jemanju vinpocetina ni treba bati.Glavni učinek pa je pemo sorazmeren stanju vašega krvnega obtoka .

Vinpocetine

Vinpocetine: “Viagra for the Brain”

Reprinted from the So Young Newsletter

Vinpocetine, powerful brain de-ager, tagged as “Viagra for the Brain,” is increasing worldwide in the treatment of cognitive deficits related to “normal” aging.

Formerly available as pricey European smart drug Cavinton (aka ARGH-4405 and Ceractin), the natural substance has recently become available as a low-cost nutritional supplement in the U.S.

Vinpocetine takes aim at the brain much the same way Viagra targets the genitals. The mechanism in both improves the blood flow, inhibiting a phosphodiesterase enzyme that degrades cyclic GMP to relax constricted arteries and smooth muscle. With Vinpocetine, cerebral microcirculation and metabolism improve and brain ATP (the cellular energy molecule) production increases along with the utilization of glucose (cellular energy food) and oxygen.

Derived from vincamine,an extract of the dwarf periwinkle plant vinca minor, the natural substance is backed by more than 20 years of clinical data for the treatment of cerebrovascular disorders and symptoms related to senility.

A “proven” long-and short-term memory booster and eyesight enhancer, its extensive medical use in cerebral circulatory disorders includes: memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness, headache, cerebro-vestibular (inner ear) problems and sensorineural hearing impairment.

Vinpocetine has “essentially revolutionized the treatment of stroke and vascular dementia,” reports David Perlmutter, M.D., “even when administered long after the initial stroke event.” Its effectiveness is likely due in part to its remarkable ability to dilate brain arteries, enhancing brain blood flow in patients with cerebrovascular disease. This improves delivery of life-giving oxygen to even marginally functioning areas of the brain.

A potent antioxidant, Vinpocetine counters “ongoing” free radical brain damage. It also reduces the “stickiness” of blood cell and platelets, to inhibit clumping tendencies (thromboses, blood clots) and the risk of stroke. Additionally, it increases elasticity of the erythrocytes, which means that red blood cells become more flexible. This enhances their ability to flow even to damaged areas of the brain.

Marketed as Cavinton in Europe by Gedeon Richter of Hungary, a series of studies conducted by the company involved 882 patients with neurological disorders ranging from stroke to cerebral insufficiency. Significant improvements were found in 62% of the patients. In one study cerebral insufficiency patients were instructed to memorize a list of 10 words. Without supplementation, the patients could memorize an average of 6 words. After a month on Vinpocetine, the average moved up to 10 words.

In another double-blind study, 22 elderly patients with central nervous system degenerative disorders were treated with Vinpocetine or placebo. Patients receiving 10 mg. of Vinpocetine three times a day for 30 days, then 5 mg. three times a day for 60 days, scored consistently better in all evaluations. CGI assessments indicated that the severity of illness decreased in 73% of the patients in the Vinpocetine group at day 30; 77% at day 90; improvement seen in 77% at day 30 and 87% at day 90. The improvement in 59% Vinpocetine-treated patients was rated good to excellent. No serious side effects were noted.

Vinpocetine’s effect on memory function was also studied in 50 patients with cerebral circulation disturbances. Improved cerebral circulation was observed after intravenous and oral administration of Vinpocetine; blood flow was most markedly increased in the brain’s gray matter. Memory capacity also improved after one month of treatment, longer-term use being associated with alleviation or complete disappearance of neurological deficit symptoms. No side effects attributed to the drug were observed.

A study to ascertain how Vinpocetine boosts cognition was undertaken in rats. A significant increase in the firing rate of neurons was noted. Since the dose of Vinpocetine used to increase electrical firing corresponded to the dose range that produced memory-enhancing effects, the results offer direct electrophysiological evidence that Vinpocetine increases the activity of ascending noradrenergic pathways, and that this effect may be related to the cognitive-enhancing characteristics of the compound.

The cognitive enhancer is also used to treat acute or chronic ophthalmological diseases of various origins, with visual acuity improving in 70% of the subjects. Product literature for Cavinton indicates its usage in cases of clogged arteries in the retina and vascular layer, in cases of degenerative changes of the yellow spot (macula) caused primarily by arteriosclerosis or angiospasm, and in cases of partial thrombosis as well as secondary glaucoma caused by the clogging of blood vessels.

Moreover, a study showed beneficial effects in protecting the retina against the hepatitis B virus (a virus that infects the heart muscle, retina, and other body parts, not only the liver).

Additionally, Vinpocetine also has been documented to partially protect against excitotoxicity induced by a wide range of glutamate-related neuro-toxins.

Vinpocetine may hold potential value for individuals who drink in excess, according to a study showing that Vinpocetine administered to rats inhibited the development of gastric lesions induced by ethanol. (Vinpocetine is a popular drug used by alcoholics in Russia to recover from gastric and neurological ethanol-induced toxicity.)

Vinpocetine has also been used successfully in offsetting space-motion sickness in experimental test subjects in both the Soviet/Russian and U.S.-manned space programs.

Beyond its medical and protective functions, Vinpocetine can boost short-term memory in healthy subjects. In a double-blind crossover study of normal, healthy women volunteers between the ages of 25 and 40 demonstrated Vinpocetine’s incredible effects. One hour after taking 40 mg. of Vinpocetine, the volunteers took the Sternberg Memory Scanning Test–a short-term memory computer-administered test. Each woman was shown one to three digits on a computer screen. One minute later, each was shown a long string of digits and was instructed to indicate whether any of the first numbers were included on the second long string. Memory time was then assessed. Women taking the placebo averaged a response in 700 milliseconds. Those taking Vinpocetine averaged under 450 milliseconds.

Gedeon Richter promotes Vinpocetine as the only drug that improves cerebral metabolism (glucose and oxygen uptake), tolerance of hypoxia (deficient blood oxygenation), ATP concentration, norepinephrine and serotin turnover, and cerebral micro-circulation. The company also claims that Vinpocetine selectively increases blood flow to the brain, improving blood flow to the impaired area without lowering blood flow to other parts of the body.

Recent studies further demonstrate that Vinpocetine offers significant and direct protection against neurological damage caused by aging. The molecular evidence indicates that the neuroprotective action of Vinpocetine is related to its ability to maintain brain cell electrical conductivity and to protect against damage caused by excessive intracellular release of calcium.

Literature shows Vinpocetine as sharing the effects of, and comparing favorably to, placebo, vincamine, papaverine, DHT (Hydergine), xanthinolnicotinate, meclophenoxate, cinnarizine, niacin, cyclandelate, difenidol, and ifenprodil.

As to its safety, more than 100 studies conducted by Gedeon Richter, have shown Vinpocetine has no drug interactions, no toxicity, and is generally very safe. Incidence of side effects using the oral supplement in humans is usually less than 1% of a study’s participants, with the unwanted effects usually disappearing with continued use. Adverse effects are rare but may include hypotenions (low blood pressure), dry mouth, weakness, and tachycardia.

A study of infants who suffered severe brain damage caused by birth trauma indicates its safety and efficacy. The study showed the infants administered Vinpocetine indicated a significant reduction or disappearance of symptoms, a decrease of intracranial hypertension, and normalization of psychomotor development.

Dosage is generally placed at 30-40 mg. daily or as prescribed by your health professional. Cost for 90/10 mg. capsules is around $18. Usage is not advised if pregnant.

While it is disquieting to think that most of us around age 30 experience a progressive decline in cognitive function, it is more than comforting to know that this is not our inevitable fate. Research and actual case studies have indicated that brain cell death can be prevented with Vinpocetine. It is conceivable to speculate that rather than face neurological impairment by the time we’re in our 80s and 90s, we can continue to develop and increase in intelligence.

(copyright Julia Busch, 2000)

***

Disclaimer

1. Consult a physician for the treatment of any disease or physical disorder.

2. We are required by law

Spoštovani!

Mene zanima, kje lahko se kupi to zdravilo?
Hvala vam!
lp, tia:-)

Zdravilo s kemičnim imenom Ethylprovincaminate je dosegljivo V Madžarski, Poljski in ZDA

Veš kaj me zanima; zakaj si se ločila?

Vzgoja in skrb za otroka je tudi dolžnost tvojega partnerja!

Vsekakor se strinjam, da je vzoga in skrb tudi dolžnost partnerja vendar pogosto pride do tega, da velik del vseh dolžnosti pade na žensko, sploh če so posredi še kakšne težave z zdravjem. Moški (nočem posploševati, seveda niste vsi enaki) pogosto bežijo od problemov. Nekaj takega je bilo tudi v mojem primeru, kar pa nisem hotela sprejeti in sem se odločila za samostojno življenje s hčerko.
Poleg tega nekateri pač nismo za skupaj. Na žalost to nekateri prepozno ugotovimo.

Lp

Dr. Rejec hvala vam za vas odgovor in še enkrat vas lepo pozdravljam!

Zivjo Tia!

Poslji mi tvoj e-mail naslov pa ti posljem stran kjer lahko omenjeno zdravilo naročiš. Če boš to storila bi rada ohranila stik s teboj, da bi si tudi kasneje lahko izmenjali izkušnje.

Lp

Spoštovani dr. Rejec

Hvala vam za tako hitri odgovor.
Zlati ste!
Lep vikend vam želim!
Lepo pozdravljeni !
tia:-)

Draga p.s.i.
Zelo bi bila vesela, da sva na zvezi in, da se pač soočima z istimi težavami.

Vesela bom, če mi boš pisala na moj e-mail: [email protected]

Lep pozdrav in si še piševa.
Bojana